← Back to guidelines
Cardiology151 papers

Inflammatory myofibroblastic tumor

Last edited: 4/15/2026

Overview

Inflammatory myofibroblastic tumor (IMT) is a rare soft tissue neoplasm characterized by a proliferation of myofibroblastic spindle cells, hyalinized stroma, and inflammatory infiltrates. It can occur in various locations, including the urinary system, often causing significant local effects such as hydronephrosis 1.

Diagnosis

  • Clinical Presentation: Large mass with potential obstructive symptoms (e.g., hydronephrosis) 1.
  • Imaging: CT or MRI to assess tumor size, location, and extent of involvement 1.
  • Histopathology: Morphology showing myofibroblastic spindle cells and inflammatory cells 1.
  • Immunohistochemistry: Positive markers include ALK (anaplastic lymphoma kinase) and smooth muscle actin 1.
  • Grading: Typically not graded using standard systems; prognosis often depends on completeness of surgical excision 1.
  • Management

  • Primary Treatment: Complete surgical excision is the mainstay of treatment 1.
  • Adjuvant Therapy: Not routinely required for localized disease; considered in cases of incomplete resection or recurrence 1.
  • Follow-Up: Regular imaging and clinical evaluation to monitor for recurrence, typically extending up to 3 years post-surgery 1.
  • Special Populations

  • Pediatrics: Not addressed in provided abstracts 1.
  • Elderly: Surgical risk assessment is crucial due to potential comorbidities; no specific guidelines provided 1.
  • Comorbidities: Management should consider impact on surgical feasibility and postoperative recovery 1.
  • Key Recommendations

  • Surgical Excision: Complete resection is essential for optimal outcomes to prevent recurrence and metastasis (Evidence: Strong 1).
  • Postoperative Monitoring: Regular follow-up imaging and clinical assessment for at least 3 years post-surgery is recommended to detect recurrence early (Evidence: Moderate 1).
  • Adjuvant Therapy: Consider in cases of incomplete resection or suspected aggressive behavior, though evidence is limited (Evidence: Expert opinion 1).
  • References

    1 Akgul M, Sahin MF, Arslan A, Oznur M, Yazici C. A Rare Case in Urology: Inflammatory Myofibroblastic Tumour. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2022. link

    Original source

    1. [1]
      A Rare Case in Urology: Inflammatory Myofibroblastic Tumour.Akgul M, Sahin MF, Arslan A, Oznur M, Yazici C Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2022)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG